Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-In-Human, Phase 1, Open-Label, Non-Randomized, Single Dose Study to Assess the Safety, Tolerability and Preliminary Efficacy of AMP-101 in Participants Diagnosed With DOK7 Congenital Myasthenic Syndrome

NCT07830563 is registered in ClinicalTrials.gov with Amplo Biotechnology as lead sponsor.

NCT NCT07830563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07830563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-In-Human, Phase 1, Open-Label, Non-Randomized, Single Dose Study to Assess the Safety, Tolerability and Preliminary Efficacy of AMP-101 in Participants Diagnosed With DOK7 Congenital Myasthenic Syndrome
Lead sponsor
Amplo Biotechnology
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
October 1, 2031
Enrollment
4 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

congenital myasthenia syndrome